Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens.

Abstract

Cytotoxic T cells recognize, via their T cell receptors (TCRs), small antigenic peptides presented by the major histocompatibility complex (pMHC) on the surface of professional antigen-presenting cells and infected or malignant cells. The efficiency of T cell triggering critically depends on TCR binding to cognate pMHC, i.e., the TCR-pMHC structural avidity. The binding and kinetic attributes of this interaction are key parameters for protective T cell-mediated immunity, with stronger TCR-pMHC interactions conferring superior T cell activation and responsiveness than weaker ones. However, high-avidity TCRs are not always available, particularly among self/tumor antigen-specific T cells, most of which are eliminated by central and peripheral deletion mechanisms. Consequently, systematic assessment of T cell avidity can greatly help distinguishing protective from non-protective T cells. Here, we review novel strategies to assess TCR-pMHC interaction kinetics, enabling the identification of the functionally most-relevant T cells. We also discuss the significance of these technologies in determining which cells within a naturally occurring polyclonal tumor-specific T cell response would offer the best clinical benefit for use in adoptive therapies, with or without T cell engineering.

• Authors: Michael Hebeisen, Mathilde Allard, Philippe O Gannon, Julien Schmidt, Daniel E Speiser, Nathalie Rufer
• Journal: Frontiers in immunology (Front Immunol) Vol. 6 Pg. 582 ( 2015) ISSN: 1664-3224 [Print] Switzerland
• PMID: 26635796 (Publication Type: Journal Article, Review)